Real-world characteristics and outcomes among patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitors in ASCO CancerLinQ’s Discovery® Database

This study sought to describe the characteristics of patients with aNSCLC receiving ICIs in the real-world, as well as to examine treatment patterns and outcomes in the time since initial ICI approval. This analysis demonstrates that aNSCLC patients receiving ICI therapy in the real-world are older than what was reported in some clinical trials, though survival outcomes were similar. Further research to examine impact of covariates on outcomes is warranted.

Read More